Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
☩Howard Morris Australia
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
☩Jill Tate Australia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada

Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Arianna Lucini Paioni
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

Area soci
Non possiedi o non ricordi la password!
Clicca qui

BC: Articoli scritti da L. Conti

Siero o plasma? Un quesito non nuovo che attende risposte nuove
Serum or plasma? An old question awaiting for new answers.
<p>There is a continual debate on what type of sample a clinical laboratory should use. While serum is still considered the gold standard and remains the required sample matrix for some assays, laboratories must consider turn-around time, which is an important metric for laboratory performance and, more importantly, plays a critical role in patient care. In addition, a body of evidence emphasize the choice of plasma samples in order to prevent modifications of some measurands due to the coagulation process and related interferences. Advantages and disadvantages of serum and plasma are discussed on the basis of current literature and evidence. In addition, data are provided on the current utilization of the matrix (serum or plasma) in Italy and in other Countries. Finally, a rational for a possible shift from serum to plasma is provided.</p>
Biochimica Clinica ; 43(2) 178-186
Documenti - Documents
Interferenze da farmaci biologici: un caso di accumulo di Bevacizumab
Interference by biological anti-cancer drugs: the case of Bevacizumab
<p>We report a case of interference with electrophoretic (CZE) and immunofixation (IFE) techniques after repeated cycles of a biological anti-cancer drug. A man, with colon neoplasia, underwent a prolonged therapy with Bevacizumab and other chemoterapeutic agents from September 2013 until May 2015. Before therapy, the electrophoretic pattern was normal while, during treatment, it showed a modification suggestive of the presence of a monoclonal component (MC) that was possible to type (IgG <span style="font-family:symbol; font-size:11.0pt">k</span>) and to quantify (8 g/L) after 22 cycles of therapy. The cooperation with clinicians and our study about biological drugs, allowed us to recognize this MC as an interference due to the accumulation of Bevacizumab in the serum of the patient. The laboratory report of a MC would have involved the patient in further procedures that are invasive, cost and time expensive. This case emphasizes the importance of a strict collaboration between physicians and the clinical laboratory in the management of patients treated with biological drugs.</p>
Biochimica Clinica ; 42(1) e05-e07
Casi clinici - Case report
Prolungamento del tempo di tromboplastina parziale attivata in una paziente asintomatica: la carenza di precallicreina
Prolonged activated partial thromboplastin time in an asymptomatic patient: the prekallikrein deficiency
<p>Prekallikrein (PK) is a contact factor of the intrinsic pathway of the coagulation cascade. Patients with PK deficiency&nbsp;usually do not show a bleeding tendency despite a prolonged activated partial thromboplastin time (aPTT) test. Here&nbsp;we report a case of a 72-years-old Caucasian woman manifesting a prolonged aPTT test. The aPTT correction after&nbsp;1:1 mixing with normal pool plasma (NPP) indicated a coagulation factor deficiency; however factors XII, XI, IX and VIII&nbsp;activities were normal. A 100:1 mixing with NPP was performed, resulting in an aPTT test correction; the aPTT test was&nbsp;then performed increasing the pre-incubation time of the patient&rsquo;s plasma. This resulted in a significant reduction of the&nbsp;aPTT. The PK deficiency was ultimately confirmed by direct measurement of PK plasma activity. This experience&nbsp;shows that PK deficiency should be considered for asymptomatic patients with prolonged aPTT and that, whenever a&nbsp;PK deficient plasma is not available, the diagnosis can be correctly oriented on the basis of simple aPTT tests.</p>
Biochimica Clinica ; 39(4) e7-e9
Casi clinici - Case report